

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

INSIDE INFORMATION GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the **“Company”**) pursuant to Rule 13.09(2)(a) of the Rules (the **“Listing Rules”**) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the **“Inside Information Provisions”**).

References are made to (i) the announcement of the Company dated September 13, 2024 in relation to the application for the H share full circulation by the Company; and (ii) the announcement of the Company dated December 19, 2024 in relation to the issuance of the Filing Notice by the CSRC for the H share full circulation application of the Company (collectively, the **“Announcements”**). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

LISTING APPROVAL BY THE STOCK EXCHANGE

The Board of the Company is pleased to announce that the Company has applied to the Listing Committee of the Stock Exchange for the approval (the **“Listing Approval”**) of the listing of 173,641,645 H shares (the **“Converted H Shares”**) of the Company to be converted under the conversion of 173,641,645 Unlisted Shares (the **“Conversion”**) held by 25 shareholders of the Company (the **“Listing”**) and the permission to deal in the Converted H Shares. The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on February 10, 2025.

Shareholding Structure

The Conversion and the Listing will involve a total of 25 participating holders of 173,641,645 Unlisted Shares and the number of the Converted H Shares held by such participating holders represents approximately 46.82% of the total issued shares of the Company as at the date of this announcement.

Set out below is the percentage holding in the Company in relation to the participating shareholders of the Unlisted Shares upon completion of the Conversion and the Listing.

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage⁽¹⁾ of the Company's total issued share capital⁽²⁾
Tetranov Pharmaceutical (Zhengzhou) Co., Ltd.*/ 鄭州泰基鴻諾醫藥股份有限公司	65,000,000	17.53%
Pivot Pharma Tech (Shanghai) Co., Ltd.*/ 貝沃特醫藥技術(上海)有限公司	5,362,500	1.45%
Chengdu Boyuan Jiayu Venture Capital Partnership (Limited Partnership)*/ 成都博遠嘉昱創業投資合夥企業(有限合夥)	5,981,019	1.61%
Changxing Liyuan Enterprise Management Partnership (Limited Partnership)*/ 長興利源企業管理合夥企業(有限合夥)	14,735,500	3.97%
Changsanjiao Tengyuan (Changxing) Medical Equity Investment Partnership (Limited Partnership)*/ 長三角騰遠(長興)醫療股權投資合夥企業(有限合夥)	8,190,000	2.21%
Zhuzhou Guochuang Junhe Investment Partnership (Limited Partnership)*/ 株洲市國創君和投資合夥企業(有限合夥)	3,510,000	0.95%
Xiamen Ronghui Hongshang Equity Investment Partnership (Limited Partnership)*/ 廈門融匯弘上股權投資合夥企業(有限合夥)	4,680,000	1.26%
Ningbo Fuqi Venture Capital Partnership (Limited Partnership)*/ 寧波複祺創業投資合夥企業(有限合夥)	4,680,000	1.26%
Shanghai Fanxi Enterprise Management Partnership (Limited Partnership)*/ 上海凡熹企業管理合夥企業(有限合夥)	390,000	0.11%
Huzhou Haibang Shuhu Venture Capital Partnership (Limited Partnership)*/ 湖州海邦數湖創業投資合夥企業(有限合夥)	1,996,800	0.54%
Changxing Guohai Donghu Equity Investment Partnership (Limited Partnership)*/ 長興國海東湖股權投資合夥企業(有限合夥)	9,139,200	2.46%
Zhuzhou Wenzhou Junzhe Venture Capital Partnership (Limited Partnership)*/ 株洲市文周君喆創業投資合夥企業(有限合夥)	3,328,000	0.90%
Jiaxing Xingren Equity Investment Partnership (Limited Partnership)*/ 嘉興行仁股權投資合夥企業(有限合夥)	1,547,619	0.42%

Name of shareholders	Number of Unlisted Shares to be converted into H Shares	Approximate percentage⁽¹⁾ of the Company's total issued share capital⁽²⁾
Hunan Xiangyi Investment Tongyuan No. 1 Venture Capital Partnership (Limited Partnership)*/ 湖南湘醫投同源壹號創業投資合夥企業(有限合夥)	3,095,238	0.83%
Shanghai Kaicheng Enterprise Management Consulting Partnership (Limited Partnership)*/ 上海凱乘企業管理諮詢合夥企業(有限合夥)	468,000	0.13%
Mr. JI Aining/ 吉愛寧	1,547,000	0.42%
Ningbo Meishan Bonded Port Area Houyang Tongchi Investment Management Partnership (Limited Partnership)*/ 寧波梅山保稅港區厚揚通馳投資管理合夥企業(有限合夥)	3,417,723	0.92%
Ningbo Meishan Bonded Port Area Houji Tongnuo Investment Management Partnership (Limited Partnership)*/ 寧波梅山保稅港區厚紀通諾投資管理合夥企業(有限合夥)	9,195,302	2.48%
Changxing Xingyin Equity Investment Partnership (Limited Partnership)*/ 長興興銀股權投資合夥企業(有限合夥)	6,509,948	1.76%
Shenzhen Yangzi Xinkang Pharmaceutical Investment Enterprise (Limited Partnership)*/ 深圳揚子鑫康醫藥投資企業(有限合夥)	4,068,718	1.10%
Yangzhou Zekang Equity Investment Partnership (Limited Partnership)*/ 揚州澤康股權投資合夥企業(有限合夥)	2,376,124	0.64%
Changxing Xinsheng Equity Investment Partnership (Limited Partnership)*/ 長興鑫晟股權投資合夥企業(有限合夥)	2,041,374	0.55%
Sichuan Huiyu Pharmaceutical Co., Ltd.*/ 四川匯宇製藥股份有限公司	6,804,580	1.83%
Changxing Caiyuan Enterprise Management Partnership (Limited Partnership)*/ 長興彩源企業管理合夥企業(有限合夥)	2,457,000	0.66%
Changxing Gangyuan Enterprise Management Partnership (Limited Partnership)*/ 長興罡源企業管理合夥企業(有限合夥)	3,120,000	0.84%
Total	173,641,645	46.82%

Note:

- (1) The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.
- (2) The calculation is based on the total number of 370,835,818 shares of the Company in issue as of the date of this announcement.

As at the date of this announcement and upon completion of the Conversion and the Listing, the share capital structure of the Company will be as follows:

Class of shares	As at the date of this announcement		Upon completion of the Conversion and the Listing	
	<i>Number of shares</i>	<i>Approximate percentage %</i>	<i>Number of shares</i>	<i>Approximate percentage %</i>
H shares	192,586,173	51.93	366,227,818	98.76
Unlisted shares	178,249,645	48.07	4,608,000	1.24
Total	370,835,818	100.00	370,835,818	100.00

Note: The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and the Listing in compliance with the requirements under the Listing Rules and applicable laws, as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the H shares of the Company.

By Order of the Board
TYK Medicines, Inc
 (浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, February 10, 2025

As at the date of this announcement, the Board comprises Dr. WU Yusheng and Dr. JIANG Mingyu as executive Directors, Dr. LI Jun, Dr. GU Eric Hong, Dr. MENG Xiaoying, Mr. HE Chao and Dr. DING Zhao as non-executive Directors, and Mr. ZHANG Senquan, Dr. LENG Yuting, Dr. XU Wenqing and Dr. SHEN Xiuhua as independent non-executive Directors.

* For identification purpose only